BioNTech (BNTX) Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Do analysts prefer GSK or BNTX?

GSK presently has a consensus target price of $37.38, suggesting a potential downside of 0.59%. BioNTech has a consensus target price of $135.91, suggesting a potential upside of 22.06%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.76

Is GSK or BNTX more profitable?

GSK has a net margin of 10.81% compared to BioNTech's net margin of -12.20%. GSK's return on equity of 49.22% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	10.81%	49.22%	11.31%
BioNTech	-12.20%	-1.84%	-1.59%

Do insiders and institutionals have more ownership in GSK or BNTX?

15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, GSK or BNTX?

GSK has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Which has better valuation and earnings, GSK or BNTX?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$40.10B	1.91	$3.29B	$2.16	17.41
BioNTech	$2.98B	8.99	-$719.92M	-$1.60	-69.59

Does the media prefer GSK or BNTX?

In the previous week, BioNTech had 11 more articles in the media than GSK. MarketBeat recorded 29 mentions for BioNTech and 18 mentions for GSK. GSK's average media sentiment score of 0.56 beat BioNTech's score of 0.32 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioNTech	11 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

GSK beats BioNTech on 9 of the 16 factors compared between the two stocks.